Tenaya Therapeutics (NASDAQ:TNYA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Tenaya Therapeutics (NASDAQ:TNYA) posted its quarterly earnings data on Wednesday. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02, FiscalAI reports. The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $0.80 million.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ TNYA opened at $0.36 on Thursday. The stock has a 50 day moving average price of $0.55 and a 200 day moving average price of $0.70. The stock has a market capitalization of $83.19 million, a PE ratio of -0.69 and a beta of 2.88. Tenaya Therapeutics has a 52 week low of $0.35 and a 52 week high of $1.56.

Wall Street Analyst Weigh In

TNYA has been the subject of a number of research reports. Wall Street Zen upgraded Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, September 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.